Janssen Biotech gets an option to Effimune's FR104; option exercised; rights returned to OSE
Executive Summary
Effimune SAS (therapeutics that regulate the immune system) granted Johnson & Johnson’s Janssen Biotech Inc. an exclusive option to develop and commercialize FR104, a preclinical monoclonal antibody fragment for immune-mediated disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice